Cardiovascular diseases are the major cause of global mortality, and often require the concomitant use of a number of drugs to prevent and reduce these deaths. The challenge is to find effective and ...

AI, omics, and systems biology can now help scientists design targeted drugs for cardiovascular disease pathways once thought "untreatable." A new article published in Frontiers in Science says these ...

Medera announced that its wholly owned preclinical subsidiary for disease modelling and drug discovery, Novoheart, has entered into a partnership with Curi Bio. This strategic collaboration integrates ...

Drug development and disease prevention of heart failure (HF) and atrial fibrillation (AF) are impeded by a lack of robust early-stage surrogates. We determined to what extent cardiac magnetic ...

SEATTLE & BOSTON--(BUSINESS WIRE)--Curi Bio, the industry leader in delivering human functional data to the drug discovery community, and Novoheart, maker of the industry’s most sophisticated and ...

Company embarks on a vision to make cardiovascular disease curable, preventable, and no longer the leading cause of death worldwide Led by founding CEO Tassos Gianakakos and fellow former MyoKardia ...

Cardiac amyloidosis is a heart condition in which abnormal proteins build up in the heart muscle, making it stiff and impairing its ability to pump blood. Multiple life-prolonging drug treatments for ...

Global drug development data and collaboration agreements show growth beyond traditional Western hubs. Efficiency gains drove ...

A recent study shows that computer algorithms can be used to find molecules that can be developed into anti-inflammatory drugs. In the article, the researchers also describe how the same strategy can ...

This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...